A 64 y/o woman with good PS had triple negative metastatic breast cancer with initial good response to docetaxel. Her her2/neu was 2+ by IHC, neg ISH. With progression, would you favor sacituzumab or trastuzumab-deruxtecan?
Both are reasonable. But I would favor sac bec if you look at the number of patient on Destiny BR04 that had TNBC it was around 60. Too small of a number. But third like I would give TDXd.
